(HealthDay News) — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news ...
Trump dismissed the order as part of what he called Biden’s “unpopular, inflationary, illegal, and radical practices.” ...
As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and ...
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...
President Donald Trump’s first moves on Medicaid and the Affordable Care Act signal his administration’s willingness to make major changes to the government programs.
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 3.6% on Friday after the U.S. Department of Health and Human ...
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started ...
The Biden Administration announced the next batch of 15 prescription drugs that will be included in price negotiations with companies — with the aim of lowering costs for people covered by Medicare.
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback